FDA panel to review once-rejected Acadia drug for psychosis

cafead

Administrator
Staff member
  • cafead   Mar 10, 2022 at 10:42: PM
via After receiving a rejection last year, Acadia said Wednesday that the Food and Drug Administration agreed to review its resubmitted application to expand use of the drug Nuplazid. The agency expects to decide on approval by Aug. 4, but will convene a group of outside advisers to weigh in.

article source